What is Protego Biopharma?
Protego Biopharma is a biopharmaceutical company dedicated to the discovery and development of first-in-class small molecule therapeutics targeting protein misfolding diseases. Leveraging a data-driven approach, the company focuses on unmet medical needs through innovative drug discovery and translational research. Their core strategy involves the use of pharmacological chaperones to restore protein stability and enhance cellular protein folding capacity, aiming to address chronic degenerative diseases such as myopathy and cardiomyopathy.
How much funding has Protego Biopharma raised?
Protego Biopharma has raised a total of $51M across 1 funding round:
Series A
$51M
Series A (2021): $51M with participation from Vida Ventures, MPM BioImpact, and Lightspeed Venture Partners
Key Investors in Protego Biopharma
Vida Ventures
Vida Ventures is a life sciences investment firm founded by experts passionate about advancing biomedical innovations. They focus on building and funding breakthroughs with the potential to make a meaningful difference for patients.
MPM BioImpact
MPM BioImpact manages venture funds focused on converting science into therapeutics. They aim to reach patients in need by investing in early-stage companies and impactful projects.
Lightspeed Venture Partners
Lightspeed Venture Partners is a global venture capital firm that invests in early and growth-stage technology companies across various sectors, partnering with founders from seed through IPO.
What's next for Protego Biopharma?
The recent major strategic investment positions Protego Biopharma for accelerated growth and the advancement of its therapeutic pipeline. This capital infusion is expected to fuel further research and development, potentially leading to clinical trials and the eventual commercialization of novel treatments for debilitating protein misfolding diseases. The company's focus on protein homeostasis and its data-driven methodology suggest a strategic expansion into new therapeutic areas and a deepening of its scientific capabilities.
See full Protego Biopharma company page
